GENE ONLINE|News &
Opinion
Blog

2021-07-04| M&ASpecial

EQT Private Equity and Goldman Sachs Spend $8.5 Billion to Acquire Parexel

by Daniel Ojeda
Share To
On July 2nd, EQT Private Equity, a Swedish firm part of EQT AB, announced it would team up with Goldman Sachs to acquire Parexel, a clinical research organization (CRO). They would buy it from its current owner Pamplona Capital Management for $8.5 billion. The announcement comes amid EQT Private Equity’s restructuring of its healthcare-related holdings.  

GO Prime with only $1.49 now

LATEST
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
2024-05-24
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
2024-05-23
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
GV Announces Cooperation with CICC
2024-05-22
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
2024-05-22
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
EVENT
Scroll to Top